THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease - PubMed
4 hours ago
- #Clinical Trial
- #IGF-1 Receptor Antagonist
- #Thyroid Eye Disease
- Veligrotug, a monoclonal antibody targeting the IGF-1 receptor, was evaluated in a phase 3 trial (THRIVE) for active thyroid eye disease.
- The study involved 113 patients randomized 2:1 to receive veligrotug or placebo over 5 infusions every 3 weeks, with assessments up to week 52.
- At week 15, veligrotug showed significant efficacy versus placebo in proptosis response (70% vs. 5%), overall response (67% vs. 5%), and diplopia improvement (59% vs. 20%).
- Response durability was observed, with 70% of initial responders maintaining proptosis improvement at week 52, and the treatment was well-tolerated with a low discontinuation rate.
- The results suggest veligrotug is a promising new treatment option for active thyroid eye disease, offering rapid and sustained benefits.